カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2017/11/15 | 1,151 | 1,163 | 1,131 | 1,144 | -11 | -1% | 72,200 |
| 2017/11/14 | 1,152 | 1,164 | 1,139 | 1,155 | +3 | +0.3% | 60,400 |
| 2017/11/13 | 1,149 | 1,167 | 1,130 | 1,152 | -73 | -6% | 162,000 |
| 2017/11/10 | 1,202 | 1,233 | 1,201 | 1,225 | +7 | +0.6% | 70,600 |
| 2017/11/09 | 1,240 | 1,243 | 1,211 | 1,218 | -40 | -3.2% | 105,000 |
| 2017/11/08 | 1,251 | 1,271 | 1,242 | 1,258 | +8 | +0.6% | 39,200 |
| 2017/11/07 | 1,275 | 1,277 | 1,250 | 1,250 | -40 | -3.1% | 94,400 |
| 2017/11/06 | 1,310 | 1,312 | 1,285 | 1,290 | -29 | -2.2% | 77,300 |
| 2017/11/02 | 1,360 | 1,360 | 1,303 | 1,319 | -39 | -2.9% | 74,300 |
| 2017/11/01 | 1,325 | 1,368 | 1,315 | 1,358 | +43 | +3.3% | 112,800 |
| 2017/10/31 | 1,307 | 1,324 | 1,294 | 1,315 | +5 | +0.4% | 49,900 |
| 2017/10/30 | 1,319 | 1,320 | 1,295 | 1,310 | -3 | -0.2% | 98,100 |
| 2017/10/27 | 1,274 | 1,315 | 1,268 | 1,313 | +45 | +3.5% | 116,600 |
| 2017/10/26 | 1,251 | 1,272 | 1,246 | 1,268 | +20 | +1.6% | 38,800 |
| 2017/10/25 | 1,265 | 1,275 | 1,248 | 1,248 | -8 | -0.6% | 54,400 |
| 2017/10/24 | 1,276 | 1,285 | 1,251 | 1,256 | -16 | -1.3% | 57,800 |
| 2017/10/23 | 1,264 | 1,274 | 1,241 | 1,272 | +8 | +0.6% | 74,300 |
| 2017/10/20 | 1,280 | 1,280 | 1,255 | 1,264 | -24 | -1.9% | 45,100 |
| 2017/10/19 | 1,244 | 1,288 | 1,244 | 1,288 | +45 | +3.6% | 65,300 |
| 2017/10/18 | 1,271 | 1,299 | 1,240 | 1,243 | -48 | -3.7% | 77,300 |
| 2017/10/17 | 1,235 | 1,345 | 1,228 | 1,291 | +69 | +5.6% | 275,300 |
| 2017/10/16 | 1,228 | 1,250 | 1,218 | 1,222 | -6 | -0.5% | 61,700 |
| 2017/10/13 | 1,218 | 1,229 | 1,206 | 1,228 | +14 | +1.2% | 62,800 |
| 2017/10/12 | 1,208 | 1,227 | 1,204 | 1,214 | ±0 | ±0% | 58,400 |
| 2017/10/11 | 1,224 | 1,224 | 1,209 | 1,214 | -11 | -0.9% | 77,300 |
| 2017/10/10 | 1,227 | 1,233 | 1,213 | 1,225 | -2 | -0.2% | 70,700 |
| 2017/10/06 | 1,262 | 1,266 | 1,220 | 1,227 | -40 | -3.2% | 115,400 |
| 2017/10/05 | 1,293 | 1,301 | 1,267 | 1,267 | -26 | -2% | 63,400 |
| 2017/10/04 | 1,320 | 1,338 | 1,285 | 1,293 | -31 | -2.3% | 79,000 |
| 2017/10/03 | 1,369 | 1,370 | 1,305 | 1,324 | -81 | -5.8% | 191,900 |
| 2017/10/02 | 1,248 | 1,441 | 1,247 | 1,405 | +157 | +12.6% | 531,900 |
| 2017/09/29 | 1,250 | 1,253 | 1,226 | 1,248 | +2 | +0.2% | 54,500 |
| 2017/09/28 | 1,232 | 1,260 | 1,229 | 1,246 | +25 | +2% | 73,100 |
| 2017/09/27 | 1,195 | 1,228 | 1,185 | 1,221 | +26 | +2.2% | 60,400 |
| 2017/09/26 | 1,204 | 1,204 | 1,190 | 1,195 | -15 | -1.2% | 51,400 |
| 2017/09/25 | 1,223 | 1,234 | 1,205 | 1,210 | -13 | -1.1% | 65,100 |
| 2017/09/22 | 1,248 | 1,253 | 1,220 | 1,223 | -36 | -2.9% | 67,700 |
| 2017/09/21 | 1,234 | 1,262 | 1,226 | 1,259 | +32 | +2.6% | 81,500 |
| 2017/09/20 | 1,237 | 1,239 | 1,225 | 1,227 | -5 | -0.4% | 46,200 |
| 2017/09/19 | 1,220 | 1,241 | 1,210 | 1,232 | +22 | +1.8% | 112,600 |
| 2017/09/15 | 1,197 | 1,218 | 1,195 | 1,210 | +7 | +0.6% | 62,600 |
| 2017/09/14 | 1,232 | 1,237 | 1,200 | 1,203 | -20 | -1.6% | 79,600 |
| 2017/09/13 | 1,226 | 1,230 | 1,202 | 1,223 | -18 | -1.5% | 90,400 |
| 2017/09/12 | 1,215 | 1,250 | 1,204 | 1,241 | +34 | +2.8% | 96,600 |
| 2017/09/11 | 1,221 | 1,237 | 1,191 | 1,207 | -9 | -0.7% | 175,900 |
| 2017/09/08 | 1,230 | 1,246 | 1,215 | 1,216 | -29 | -2.3% | 59,400 |
| 2017/09/07 | 1,254 | 1,274 | 1,211 | 1,245 | -12 | -1% | 102,400 |
| 2017/09/06 | 1,179 | 1,284 | 1,177 | 1,257 | +4 | +0.3% | 157,400 |
| 2017/09/05 | 1,347 | 1,347 | 1,243 | 1,253 | -85 | -6.4% | 228,200 |
| 2017/09/04 | 1,364 | 1,365 | 1,327 | 1,338 | -43 | -3.1% | 175,400 |
1701～
1750
件表示中 / 3572件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 30,400円 | -43.1% | - | 0.00% | - | 1.81倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| カイオム | 9,900円 | +2.6% | - | 0.00% | - | 5.73倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
| ＶＩＳ | 91,000円 | +87.8% | +265.7% | 0.00% | 54.65倍 | 2.51倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 82,300円 | +14.5% | - | 0.00% | - | 2.43倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| ＤＥＬＴＡ－Ｐ | 65,800円 | - | - | 0.00% | - | 4.40倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
市場注目の銘柄
チャート関連のコラム
